CN108888715B - Composition, preparation method and application thereof - Google Patents
Composition, preparation method and application thereof Download PDFInfo
- Publication number
- CN108888715B CN108888715B CN201810868058.6A CN201810868058A CN108888715B CN 108888715 B CN108888715 B CN 108888715B CN 201810868058 A CN201810868058 A CN 201810868058A CN 108888715 B CN108888715 B CN 108888715B
- Authority
- CN
- China
- Prior art keywords
- composition
- parts
- asthma
- extracting
- kelp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 48
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 206010011224 Cough Diseases 0.000 claims abstract description 27
- 208000006673 asthma Diseases 0.000 claims abstract description 23
- 241000512259 Ascophyllum nodosum Species 0.000 claims abstract description 19
- 241001076416 Dendrobium tosaense Species 0.000 claims abstract description 18
- 235000007516 Chrysanthemum Nutrition 0.000 claims abstract description 14
- 235000009008 Eriobotrya japonica Nutrition 0.000 claims abstract description 12
- 244000061508 Eriobotrya japonica Species 0.000 claims abstract 2
- 239000000284 extract Substances 0.000 claims description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- 238000001035 drying Methods 0.000 claims description 14
- 238000001914 filtration Methods 0.000 claims description 14
- 238000007873 sieving Methods 0.000 claims description 14
- 241000723353 Chrysanthemum Species 0.000 claims description 13
- 239000007788 liquid Substances 0.000 claims description 11
- 230000001965 increasing effect Effects 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 238000010298 pulverizing process Methods 0.000 claims description 7
- 238000002791 soaking Methods 0.000 claims description 7
- 239000000469 ethanolic extract Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 206010036790 Productive cough Diseases 0.000 claims description 3
- 208000024794 sputum Diseases 0.000 claims description 3
- 210000003802 sputum Anatomy 0.000 claims description 3
- 206010013789 Dry throat Diseases 0.000 claims description 2
- 206010043521 Throat irritation Diseases 0.000 claims description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 abstract description 11
- 208000026435 phlegm Diseases 0.000 abstract description 11
- 230000001603 reducing effect Effects 0.000 abstract description 10
- 201000010099 disease Diseases 0.000 abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 9
- 210000004072 lung Anatomy 0.000 abstract description 9
- 206010006451 bronchitis Diseases 0.000 abstract description 8
- 206010061218 Inflammation Diseases 0.000 abstract description 4
- 230000004054 inflammatory process Effects 0.000 abstract description 4
- 230000003647 oxidation Effects 0.000 abstract description 3
- 238000007254 oxidation reaction Methods 0.000 abstract description 3
- 239000013618 particulate matter Substances 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 abstract 1
- 241000605372 Fritillaria Species 0.000 abstract 1
- 230000009285 allergic inflammation Effects 0.000 abstract 1
- 208000026106 cerebrovascular disease Diseases 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 231100000957 no side effect Toxicity 0.000 abstract 1
- 230000001766 physiological effect Effects 0.000 abstract 1
- 230000035790 physiological processes and functions Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 14
- 239000013641 positive control Substances 0.000 description 13
- 238000012360 testing method Methods 0.000 description 11
- 241001092070 Eriobotrya Species 0.000 description 10
- 239000002245 particle Substances 0.000 description 10
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 7
- 244000128583 Coreopsis cardaminifolia Species 0.000 description 6
- 235000005912 Coreopsis cardaminifolia Nutrition 0.000 description 6
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 6
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 5
- 206010006458 Bronchitis chronic Diseases 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 235000011114 ammonium hydroxide Nutrition 0.000 description 5
- 208000007451 chronic bronchitis Diseases 0.000 description 5
- 210000005069 ears Anatomy 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 210000002345 respiratory system Anatomy 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 241000700198 Cavia Species 0.000 description 4
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 4
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 230000007365 immunoregulation Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 241001547127 Fritillaria cirrhosa Species 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- DBTMGCOVALSLOR-DEVYUCJPSA-N (2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](CO)O[C@H](O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-DEVYUCJPSA-N 0.000 description 2
- 208000014085 Chronic respiratory disease Diseases 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 229920001543 Laminarin Polymers 0.000 description 2
- 239000005717 Laminarin Substances 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000723366 Coreopsis Species 0.000 description 1
- 206010014025 Ear swelling Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 241001644295 Fritillaria przewalskii Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 244000016296 Jacobaea maritima Species 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 240000001307 Myosotis scorpioides Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 210000003489 abdominal muscle Anatomy 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- JUGOREOARAHOCO-UHFFFAOYSA-M acetylcholine chloride Chemical compound [Cl-].CC(=O)OCC[N+](C)(C)C JUGOREOARAHOCO-UHFFFAOYSA-M 0.000 description 1
- 229960004266 acetylcholine chloride Drugs 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000009798 acute exacerbation Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 210000005091 airway smooth muscle Anatomy 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 229960001660 histamine phosphate Drugs 0.000 description 1
- ZHIBQGJKHVBLJJ-UHFFFAOYSA-N histamine phosphate Chemical compound OP(O)(O)=O.OP(O)(O)=O.NCCC1=CNC=N1 ZHIBQGJKHVBLJJ-UHFFFAOYSA-N 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229960001317 isoprenaline Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 230000010349 pulsation Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000009692 water atomization Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8966—Fritillaria, e.g. checker lily or mission bells
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8984—Dendrobium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Polymers & Plastics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a composition for remarkably reducing diseases caused by haze particulate matter inhalation, which comprises fritillaria, loquat leaves, dendrobium officinale, kelp and snow chrysanthemum. The invention also provides a preparation method and application of the composition. The composition has remarkable physiological activities and functions of relieving cough, relieving asthma, moistening lung, reducing phlegm, clearing heat from throat, relieving inflammation, resisting oxidation and the like, can be used for preventing and treating bronchitis, asthma, cardiovascular and cerebrovascular diseases and allergic inflammation caused by particulate matter inhalation in haze weather, has no side effect, and can be used for a long time.
Description
Technical Field
The invention relates to a composition, and belongs to the field of medicines.
Technical Field
With the rapid development of modern industry, various pollutions are more and more serious, the air quality is seriously influenced, the haze weather frequently appears, and great harm is brought to the health of human bodies. Sulfur dioxide, nitrogen oxides and inhalable particles are main components of haze, the sulfur dioxide, the nitrogen oxides and the inhalable particles are gaseous pollutants, and the particles are the main culprits for aggravating haze weather pollution. The particles are combined with the fog to make the sky become grey instantly. In haze weather, inhalable particles (PM10) and fine particles (PM2.5) are increased obviously, the particles can directly enter and adhere to the respiratory tract and the alveoli of a human body, especially submicron particles can be deposited in the upper respiratory tract, the lower respiratory tract and the alveoli respectively to cause diseases such as acute rhinitis and acute bronchitis. For patients with chronic respiratory diseases such as bronchial asthma, chronic bronchitis, obstructive emphysema and chronic obstructive pulmonary disease, the disease can be acute-onset or acute-aggravated in haze weather. The most obvious phenomenon is that people in haze weather have serious cough, more sputum and inflamed respiratory tract, thereby causing a series of respiratory diseases. In addition, in haze weather, the heart pulsation is accelerated due to low oxygen content of air, so that people feel stuffy in chest and short in breath, and the harm to the old is large; in haze weather, the sunlight cannot irradiate the ground, or the sunlight is weak, so that bacteria, viruses and microorganisms on the ground surface can be rapidly propagated, and diseases such as allergy are caused; haze weather is dark and cloudy, air is dirty, the mood of people can also become low, and the mood is irritated. Therefore, the research and development of products for preventing the absorption of particles in the haze weather or preventing and treating diseases caused by the absorption of the particles in the haze weather are of great significance.
The invention content is as follows:
the invention aims to overcome the defects of the prior art and provides a composition and a preparation method thereof.
One of the objects of the present invention is achieved by the following means.
A composition comprising the following components by weight: 2-6 parts of bulbus fritillariae cirrhosae, 3-7 parts of loquat leaves, 1-4 parts of dendrobium officinale, 2-5 parts of kelp and 2-5 parts of snow chrysanthemum.
Preferably, the composition comprises the following components in parts by weight: 4-6 parts of bulbus fritillariae cirrhosae, 3-4 parts of loquat leaves, 1-2 parts of dendrobium officinale, 3-4 parts of kelp and 2-4 parts of snow chrysanthemum.
Bulbus Fritillariae Cirrhosae, being slightly cold in nature, bitter and sweet in taste, enters lung and heart meridians, has the effects of relieving cough, eliminating phlegm, clearing heat, resolving masses, moistening lung and relieving asthma, is always the key medicine for clearing heat, moistening lung, relieving cough and eliminating phlegm, can increase secretion amount and secretion speed of glands in airways, effectively reduces viscosity of sputum, can relax airway smooth muscles, relieve airway spasm and has the effects of relieving spasm and asthma.
Loquat leaves, which are dry leaves of loquat belonging to the family Rosaceae, are bitter in taste and slightly cold in nature, enter the lung channel and the stomach channel, have a certain anti-infection effect on chronic bronchitis, and have good cough relieving, phlegm eliminating and asthma relieving effects.
The kelp, salty and cold, entering liver, stomach and kidney meridians, can soften hardness and dissipate stagnation, eliminate phlegm and promote diuresis (relieve cough), can remove pathological products and pathogenic factors of chronic bronchitis aiming at the pathogenesis of the chronic bronchitis, recover the dispersing and purifying functions of the lung and play a role in treating both principal and secondary aspect of disease; modern pharmacological research shows that laminarin can relieve respiratory inflammatory reaction of asthmatic mice to a certain extent, and the laminarin also has the functions of antibiosis, antivirus, antioxidation, immunoregulation and the like.
Dendrobium officinale, sweet in flavor and slightly cold in nature, enters stomach and kidney meridians, and is recorded in Ben Cao gang mu Shi Yi (supplement to compendium of materia Medica) as "clearing stomach, removing deficiency heat and promoting the production of body fluid". Modern pharmacological researches find that the dendrobium officinale mainly has pharmacological effects of enhancing immunity, resisting fatigue, resisting oxidation, promoting digestion, promoting salivary secretion, reducing blood sugar, reducing blood pressure, resisting liver injury, resisting tumors and the like.
Coreopsis tinctoria and senecio cineraria which are perennial herb plants of Coreopsis of Compositae, have sweet taste and mild nature, and have the effects of clearing heat and removing toxicity, promoting blood circulation and removing blood stasis and the like. Modern pharmacological research finds that the compound has activities of resisting inflammation, oxidation, virus and the like.
The fritillaria cirrhosa, the loquat leaves and the kelp in the composition have the effects of relieving cough, reducing phlegm, relieving asthma and the like, but the three have different action mechanisms, the combined application can improve the curative effect through the multi-target effect, and the fritillaria cirrhosa and the loquat leaves enter lung channels, so that the kelp can be introduced into the lung to enhance the lung moistening and phlegm reducing effects of the fritillaria cirrhosa, the loquat leaves and the kelp. The dendrobium officinale can promote the production of body fluid to quench thirst, and the coreopsis tinctoria can clear away heat and toxic materials, and can improve pharyngeal discomfort symptoms caused by bronchitis and the like by combined application. And the dendrobium officinale, the kelp and the snow chrysanthemum have good anti-inflammatory, antioxidant and immunoregulation effects in combined application, and modern researches prove that many lung diseases are closely related to inflammatory exudation, oxidative stress, free radical damage, immune response and the like, so that the antiviral, antibacterial, antioxidant and immunoregulation effects of the dendrobium officinale, the kelp and the snow chrysanthemum can play an auxiliary role in treating acute attack of chronic bronchitis and can inhibit the occurrence of diseases such as pulmonary fibrosis.
All medicinal materials in the composition are safe and non-toxic, and the composition is reasonable in compatibility, has good effects of relieving cough, reducing phlegm, relieving asthma, clearing throat and the like, also has certain anti-inflammatory, antioxidant and immunoregulation effects, can be used for a series of diseases caused by haze particulate inhalation, and can prevent acute attack or acute exacerbation of chronic respiratory diseases.
In conclusion, the composition of the invention is applied to medicines for treating cough, excessive phlegm, asthma and dry and itchy throat.
The invention also provides a preparation method of the composition, which mainly comprises the following steps:
(1) taking kelp and dendrobium officinale according to a formula ratio, adding water according to a material-to-liquid ratio of 1:20-40, soaking for 20-40 minutes, extracting at 90 ℃ for 1-3 times, each time for 1-2 hours, filtering to obtain an extracting solution, concentrating and drying the extracting solution to constant weight to obtain a dry extract, and crushing and sieving to obtain a mixed water extract;
(2) extracting folium Eriobotryae, snow chrysanthemum and Bulbus Fritillariae Cirrhosae with 60-85% ethanol at a ratio of 1:8-15 for 1-3 times, each for 1-2h, filtering to obtain extractive solution, concentrating and drying to constant weight to obtain dry extract, pulverizing and sieving to obtain mixed ethanol extract;
(3) and (3) mixing the dry paste powder prepared in the steps (1) and (2) in an equivalent increasing mode to obtain the composition for reducing the diseases caused by the suction of the haze particles.
The composition can be added with or without pharmaceutically acceptable auxiliary materials to prepare oral preparations such as instant powder, granules, tablets, capsules, pills, solutions and the like.
The specific implementation mode is as follows:
the invention is further illustrated by the following specific examples, which are not intended to be limiting in any way, and any variations or alterations based on the teachings of the present invention are intended to be within the scope of the invention.
Example 1
Prescription: bulbus Fritillariae Cirrhosae 6g, folium Eriobotryae 4g, herba Dendrobii 2g, thallus laminariae 3g, and coreopsis tinctoria 4 g.
The preparation method comprises the following steps:
(1) taking kelp and dendrobium officinale according to a formula ratio, adding water according to a material-to-liquid ratio of 1:20, soaking for 30 minutes, extracting for 2 times at 90 ℃ for 1 hour each time, filtering to obtain an extracting solution, concentrating and drying the extracting solution to constant weight to obtain a dry extract, crushing and sieving to obtain a mixed water extract;
(2) extracting folium Eriobotryae, snow chrysanthemum and Bulbus Fritillariae Cirrhosae with 60% ethanol at a ratio of 1:8 for 3 times (1 hr each time), filtering to obtain extractive solution, concentrating and drying to constant weight to obtain dry extract, pulverizing and sieving to obtain mixed ethanol extract;
(3) mixing the dry extract powders obtained in the steps 1 and 2 in an equivalent increasing way to obtain the composition.
The prepared composition can be made into hard capsules by adding auxiliary materials according to the conventional capsule preparation process.
Example 2
Prescription: bulbus Fritillariae Cirrhosae 2g, folium Eriobotryae 7g, herba Dendrobii 1g, thallus laminariae 5g, and coreopsis tinctoria 5 g.
(1) Taking the kelp and the dendrobium officinale according to the formula proportion, and mixing the kelp and the dendrobium officinale according to the material-liquid ratio of 1: 40 adding water, soaking for 20 min, extracting at 90 deg.C for 1 time, each time for 2 hr, filtering to obtain extractive solution, concentrating and drying to constant weight to obtain dry extract, pulverizing and sieving to obtain mixed water extract;
(2) extracting loquat leaves, snow chrysanthemum and bulbus fritillariae cirrhosae with 85% ethanol according to a formula proportion, wherein the material-liquid ratio is 1: 15, extracting for 1 time, each time for 2 hours, filtering to obtain an extracting solution, concentrating and drying the extracting solution to constant weight to obtain a dry extract, and crushing and sieving to obtain a mixed alcohol extract;
(3) mixing the dry extract powders obtained in the steps 1 and 2 in an equivalent increasing way to obtain the composition.
The prepared composition can be added with auxiliary materials and then prepared into granules according to the conventional granule preparation process
Example 3
Prescription: bulbus Fritillariae Cirrhosae 4g, folium Eriobotryae 5g, herba Dendrobii 1.5g, thallus laminariae 4g, and coreopsis tinctoria 3.5 g.
(1) Taking kelp and dendrobium officinale according to a formula ratio, adding water according to a material-to-liquid ratio of 1:30, soaking for 40 minutes, extracting for 3 times at 90 ℃ for 1 hour each time, filtering to obtain an extracting solution, concentrating and drying the extracting solution to constant weight to obtain a dry extract, crushing and sieving to obtain a mixed water extract;
(2) extracting folium Eriobotryae, snow chrysanthemum and Bulbus Fritillariae Cirrhosae with 75% ethanol at a ratio of 1:10 for 2 times (1 h each time), filtering to obtain extractive solution, concentrating and drying to constant weight to obtain dry extract, pulverizing and sieving to obtain mixed ethanol extract;
(3) mixing the dry extract powders obtained in the steps 1 and 2 in an equivalent increasing way to obtain the composition.
The prepared composition can be prepared into liquid agent according to the conventional liquid agent preparation process.
Example 4
Prescription: 5g of bulbus fritillariae cirrhosae, 3g of loquat leaf, 4g of dendrobium officinale, 2g of kelp and 2g of snow chrysanthemum.
(1) Taking the kelp and the dendrobium officinale according to the formula proportion, adding water according to the material-liquid ratio of 1:25, soaking for 30 minutes, extracting for 2 times at 90 ℃ for 1 hour each time, filtering to obtain an extracting solution, concentrating and drying the extracting solution to constant weight to obtain a dry extract, crushing and sieving to obtain a mixed water extract;
(2) extracting folium Eriobotryae, snow chrysanthemum and Bulbus Fritillariae Cirrhosae with 70% ethanol at a ratio of 1:12 for 3 times (1 hr each time), filtering to obtain extractive solution, concentrating and drying to constant weight to obtain dry extract, pulverizing and sieving to obtain mixed ethanol extract;
(3) mixing the dry extract powders obtained in the steps 1 and 2 in an equivalent increasing way to obtain the composition.
The prepared composition can be made into tablets by adding auxiliary materials according to the conventional tablet preparation process.
Example 5
Prescription: bulbus Fritillariae Cirrhosae 4.5g, folium Eriobotryae 4g, herba Dendrobii 3g, thallus laminariae 4g, and coreopsis tinctoria 4 g.
(1) Taking kelp and dendrobium officinale according to a formula ratio, adding water according to a material-to-liquid ratio of 1:30, soaking for 30 minutes, extracting for 2 times at 90 ℃ for 2 hours each time, filtering to obtain an extracting solution, concentrating and drying the extracting solution to constant weight to obtain a dry extract, crushing and sieving to obtain a mixed water extract;
(2) extracting folium Eriobotryae, snow chrysanthemum and Bulbus Fritillariae Cirrhosae with 75% ethanol at a ratio of 1:13 for 3 times (1 h each time), filtering to obtain extractive solution, concentrating and drying to constant weight to obtain dry extract, pulverizing and sieving to obtain mixed ethanol extract;
(3) mixing the dry extract powders obtained in the steps 1 and 2 in an equivalent increasing way to obtain the composition.
The prepared composition can be added with auxiliary materials and then prepared into pills according to the conventional pill preparation process.
The following experimental examples show that the composition of the invention has the efficacies of relieving cough, reducing phlegm, clearing heat from throat, relieving asthma, resisting inflammation and the like.
Test example 1 Ammonia water cough-inducing test
50 KM mice with the weight of 18-22 g are respectively placed in 500ml beakers, 13% concentrated ammonia water atomization gas is introduced by an ultrasonic atomizer, and the process is stopped after 5 s. And (3) taking out the mice, timing from the introduction of concentrated ammonia water atomized gas, and discarding the mice which do not have cough (insensitive to ammonia water) and the mice which have cough times more than 50 (over-sensitive) within 3 min. After resting for 3 days, taking 36 qualified mice, randomly dividing into 3 groups, namely a blank group, a positive control group (0.2 ml/mouse of Jingdu Mici-ci-honey refining Sichuan fritillary bulb loquat cream group) and a composition group (0.45g/kg), and carrying out intragastric administration for 1 time every day and continuously carrying out administration for 7 days. After 30min of the last administration, ammonia water induced cough test was performed again in the same way, and the time (i.e. cough latency) and the number of times of cough (based on contraction or contraction of abdominal muscles and simultaneous expansion of mouth of the mouse, sometimes accompanied by cough) from the start of ammonia gas introduction to the first cough within 3min of the mouse were recorded. The results of the experimental analyses are shown in Table 1.
TABLE 1 measurement results of cough latency and cough frequency of mice in each group
| Group of | Cough latency, S | Number of coughs (3) |
| Blank control group | 40.97±9.69 | 60±14.35 |
| Positive control group | 65.89±13.89* | 15±5.1** |
| Composition set | 69.89±12.28* | 10±4.89** |
Note: comparison with blank group, P*＜0.05，P**＜0.01
Compared with a blank control group, the cough incubation period of mice in the composition group and the positive control group is prolonged, the cough frequency is obviously reduced, and the composition group is superior to the positive control group, which shows that the composition has an obvious cough relieving effect.
Test example 2 mouse tracheal phenol Red excretion test
The grouping and administration method of the experimental animals are the same as those of test example 1, and 30min after the last administration, 0.5% phenol red normal saline solution is injected into the abdominal cavity, cervical dislocation is killed after 30min, the skin in front of the neck is cut, the trachea is separated, and 1.5ml of 5% sodium bicarbonate solution is absorbed to lavage the respiratory tract. Collecting lavage liquid, centrifuging, collecting supernatant, measuring OD value at wavelength of 558nm, and calculating phenol red concentration according to phenol red standard curve regression equation, with the experimental results shown in Table 2.
TABLE 2 measurement results of the amount of tracheal phenol red excretion in each group of mice
| Group of | Phenol Red concentration (ug/ml) |
| Blank control group | 0.75±0.15 |
| Positive control group | 1.16±0.25* |
| Composition set | 1.81±0.12** |
Note: comparison with blank group, P*＜0.05，P**＜0.01
Compared with a blank control group, the composition group and the positive control group have increased airway phenol red excretion amount of mice, and the difference of the composition group has significance, which indicates that the composition has the effect of reducing phlegm.
Test example 3 Histamine-acetylcholine-induced asthma in Guinea pig test
50 white guinea pigs, half male and female, weighing 220-270g, were sprayed into the chamber for 10s using a multifunctional cough and asthma inducing instrument (0.1% histamine phosphate and 2% acetylcholine chloride mixed in an equivalent amount of 1: 1), observed and recorded asthma inducing latency (time from spraying to the onset of convulsion and falling) for over 120s, and discarded. The experimental animals were grouped and administered in the same manner as in test example 1, the positive drug was inhaled isoprenaline 15s by aerosol before asthma induction, and administered by gavage once a day for 5 days, and the asthma induction experiment was repeated 1h after the last administration by the above screening method, and the asthma induction latency of guinea pigs was observed and recorded. The results are shown in Table 3
TABLE 3 determination of the asthma-inducing incubation period in the guinea pigs of each group
| Group of | Asthma incubation period before administration (S) | Latent period of asthma(s) after administration |
| Blank control group | 65.2±12.1 | 63±14.35 |
| Positive control group | 67.60±11.89 | 135±45.1** |
| Composition set | 65.89±12.28 | 185±34.89** |
Note: comparison with blank group, P*＜0.05，P**＜0.01
The blank control group, the positive control group and the composition group lead latency period before sample administration have no statistical difference, have comparability and establish model building. After the administration, the asthma-inducing incubation periods of the guinea pigs in the composition group and the positive control group are both obviously increased, and the composition group is superior to the positive control group, which shows that the composition has an obvious asthma-relieving effect.
Test example 4 mouse ear swelling test
36 KM mice are male, the weight is 18-22 g, the experimental animals are grouped and the sample dose is the same as that of experimental example 1, aspirin (0.25g/kg) is administered to a positive control group once a day for 7 days continuously, and distilled water with the same volume is administered to a blank group. The mice are fasted for 12 hours before the last sample administration without water prohibition, 20ul of dimethylbenzene is uniformly smeared in the center of the right auricle of the mice after the last sample administration for 40min, the mice are killed by taking off the cervical vertebra after free diffusion for 30min, the ears are cut off, the ears are punched at the same parts of the ears by a 9mm puncher and weighed, and the auricle swelling rate of the mice is calculated by taking the weight difference of the ears as the auricle swelling value. The results are shown in Table 4.
Auricle swelling value (mg) ═ right ear weight (mg) -left ear weight (mg)
TABLE 4 results of Effect of the samples on anti-inflammatory action in mice
| Group of | Difference between left and right ears | Swelling inhibition ratio (%) |
| Blank control group | 10.52±3.16 | - |
| Positive control group | 3.67±0.85** | 67％ |
| Composition set | 3.47±0.98** | 65％ |
Note: comparison with blank group, P*＜0.05，P**＜0.01
Compared with a blank control group, the composition group and the positive control group can obviously inhibit the mouse auricle swelling caused by the dimethylbenzene, which indicates that the composition has good anti-inflammatory effect.
The above description is only for the preferred embodiment of the present invention, and is not intended to limit the scope of the present invention. Any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention shall fall within the protection scope of the present invention.
Claims (2)
1. A composition, characterized in that it consists of, by weight: 2-6 parts of bulbus fritillariae cirrhosae, 3-7 parts of loquat leaves, 1-4 parts of dendrobium officinale, 2-5 parts of kelp and 2-5 parts of snow chrysanthemum; the preparation method of the composition comprises the following steps:
(1) taking kelp and dendrobium officinale according to a formula ratio, adding water according to a material-to-liquid ratio of 1:20-40, soaking for 20-40 minutes, extracting at 90 ℃ for 1-3 times, each time for 1-2 hours, filtering to obtain an extracting solution, concentrating and drying the extracting solution to constant weight to obtain a dry extract, and crushing and sieving to obtain a mixed water extract;
(2) extracting folium Eriobotryae, snow chrysanthemum and Bulbus Fritillariae Cirrhosae with 60-85% ethanol at a ratio of 1:8-15 for 1-3 times, each for 1-2h, filtering to obtain extractive solution, concentrating and drying to constant weight to obtain dry extract, pulverizing and sieving to obtain mixed ethanol extract;
(3) and (3) mixing the dry paste powder prepared in the steps (1) and (2) in an equivalent increasing mode to obtain the composition.
2. Use of a composition according to claim 1 for the preparation of a medicament for cough, profuse sputum, asthma, dry and itchy throat.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810868058.6A CN108888715B (en) | 2018-08-02 | 2018-08-02 | Composition, preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810868058.6A CN108888715B (en) | 2018-08-02 | 2018-08-02 | Composition, preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108888715A CN108888715A (en) | 2018-11-27 |
| CN108888715B true CN108888715B (en) | 2021-03-23 |
Family
ID=64353121
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810868058.6A Active CN108888715B (en) | 2018-08-02 | 2018-08-02 | Composition, preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108888715B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105660951A (en) * | 2016-02-22 | 2016-06-15 | 广西梧州制药（集团）股份有限公司 | Healthcare tea for preventing and treating respiratory system diseases caused by haze and preparation method thereof |
| CN107279610A (en) * | 2017-05-25 | 2017-10-24 | 杨文秀 | A kind of pears radish composite health care beverage moistened the lung and relieve the cough and preparation method |
-
2018
- 2018-08-02 CN CN201810868058.6A patent/CN108888715B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105660951A (en) * | 2016-02-22 | 2016-06-15 | 广西梧州制药（集团）股份有限公司 | Healthcare tea for preventing and treating respiratory system diseases caused by haze and preparation method thereof |
| CN107279610A (en) * | 2017-05-25 | 2017-10-24 | 杨文秀 | A kind of pears radish composite health care beverage moistened the lung and relieve the cough and preparation method |
Non-Patent Citations (1)
| Title |
|---|
| 昆仑雪菊搭配铁皮石斛食用功效好;藏区特产;《西藏商城藏善堂移动站》;20151224;https://m.xizangshop.com/article.php?id=1679 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108888715A (en) | 2018-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2450046B1 (en) | A medicinal composition for the treatment of bronchitis and preparation thereof | |
| CN103127369A (en) | Traditional Chinese medicine composition for treating respiratory tract haze disoperation and preparation method | |
| CN106138360A (en) | A kind of Chinese medicine composition and preparation method thereof, application | |
| WO2021227614A1 (en) | Pharmaceutical composition for clearing lung and pulmonary fibrosis and use thereof | |
| CN104381703A (en) | Dog food and preparation method thereof | |
| CN108888715B (en) | Composition, preparation method and application thereof | |
| CN109239239B (en) | Traditional Chinese medicine composition for clearing lung, eliminating phlegm, relieving cough and asthma and preparation method and application thereof | |
| CN107753664B (en) | Traditional Chinese medicine composition for treating allergic rhinitis and preparation method thereof | |
| CN105963410B (en) | Traditional Chinese medicine composition with cough relieving function and preparation thereof | |
| CN113633730A (en) | Traditional Chinese medicine composition for treating asthma and preparation method thereof | |
| CN115990228B (en) | Preparation method and application of traditional Chinese medicine composition for relieving pharyngitis, relieving cough and reducing sputum | |
| CN110917271A (en) | Spray for preventing and treating allergic asthma combined allergic rhinitis of children and teenagers | |
| CN116531457B (en) | Traditional Chinese medicine composition for treating chronic pharyngitis and application thereof | |
| CN112007116A (en) | honeysuckle-Chinese olive tea with effects of clearing heat from throat, moistening lung and clearing away heat and preparation method thereof | |
| CN116211993B (en) | Composition for treating senile chronic disease and its preparation method | |
| CN114010691B (en) | Qingyu throat-benefiting buccal tablet and preparation method thereof | |
| CN109820826B (en) | Anti-inflammatory traditional Chinese medicine granules and preparation method thereof | |
| CN106963833B (en) | Medicine for treating cold of children and adults and preparation method thereof | |
| CN103623203B (en) | A kind of preparation method of dimethoxanate oral formulations | |
| CN108815376B (en) | Throat-clearing and sore-throat-relieving tea | |
| CN111388617B (en) | Traditional Chinese medicine composition for eliminating phlegm and relieving cough and preparation method thereof | |
| CN107029139B (en) | Traditional Chinese medicine composition and preparation for clearing phlegm and moistening lung and preparation method thereof | |
| CN118477118A (en) | Chinese herbal compound buccal tablet for treating upper respiratory tract infection of children and protecting stomach and strengthening body resistance and preparation method thereof | |
| CN116211932A (en) | Medicine for treating rhinitis combined with acute pharyngitis caused by wind-heat of lung channel and preparation method thereof | |
| CN118845946A (en) | Compound dendrobium huoshanense lozenge capable of clearing heat from throat and protecting throat |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20230309 Address after: No. 1805, Floor 15, Building 3, Yard 93, Jianguo Road, Chaoyang District, Beijing, 100026 Patentee after: Beijing Zhonghong Ruixing Technology Co.,Ltd. Address before: Room 211-1, second floor, building a, Yunnan Overseas Students Pioneer Park Phase I base, University Science Park, 1520 Haiyuan Middle Road, incubator management center, Kunming high tech Zone, Yunnan Province, 650106 Patentee before: YUNNAN DECAITANG BIOMEDICAL TECHNOLOGY CO.,LTD. |